The development of PtIV prodrugs that are reduced into the therapeutically active PtII
species within the tumor microenvironment has received much research interest. In order to …

The development of PtIV prodrugs which are selectively reduced within cancerous cells into
their PtII therapeutically active species has received increasing attention within the last …

Despite the great success achieved by photoactivated chemotherapy, eradicating deep
tumors using external sources with high tissue penetration depth remains a challenge. Here …

Platinum‐based drugs are among the most active antitumor reagents in clinical practice;
their application is limited by side effects and drug resistance. A novel and personalized …

Cisplatin has long been the first line of treatment for a variety of solid tumors. However, poor
pharmacokinetics and high incidences of resistance in the clinic have motivated the …

Targeted anticancer prodrugs that can be controllably activated are highly desired for
personalized precision medicine in cancer therapy. Such prodrugs with unique action …

The most widely used anticancer drugs are platinum-based. Their efficacy might be
improved by carriers which can transport large numbers of Pt centres, shield the drug from …

Despite remarkable progress in cancer therapeutics, substantial impediments are still
unresolved, such as severe adverse reactions and poor effectiveness against multidrug …

A novel and highly efficient dual‐targeting platform was designed to ensure targeted in vivo
delivery of dual‐action PtIV prodrugs. The dual targeting was established by liposomal …

Tumor‐targeted and stimuli‐activatable nanosensitizers are highly desirable for cancer
theranostics. However, designing smart nanosensitizers with multiple imaging signals and …